Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Français (Suisse)
Italiano
Nederlands (Nederland)
Nederlands (België)
MARKETS
Equities
United States
North America
Europe
Asia
Middle East
More Equities
Indexes
S&P 500
DOW JONES
NASDAQ 100
EURO STOXX 50
NIKKEI 225
More Indexes
Currency / Forex
USD / EUR
USD / CAD
USD / MXN
USD / BRL
USD / INR
More Currencies
Commodities
GOLD
CRUDE OIL (WTI)
CRUDE OIL (BRENT)
SILVER
PLATINUM
More Commodities
Cryptocurrencies
BITCOIN
ETHEREUM
Trackers & ETF
Rankings and News
Advanced Search
NEWS
Latest News
Companies
Markets
Economy
Currency / Forex
Commodities
Interest Rates
Finance Pro.
Business Leaders
Cryptocurrencies
Cybersecurity
Economic Calendar
Listed companies
Analyst Reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit Warnings
Appointments
Press Releases
Events
Security Transactions
Financial Calendar
Sector News
Energy
Basic Materials
Industrials
Consumer Cyclical
Consumer Non-Cyclical
Financials
Healthcare
Technology
Real Estate
Utilities
ANALYSIS
All Analysis
Must Read
Weekly market update
Stock Trading Strategies
STOCK PICKS
All Stock Picks
Subscribe
PORTFOLIOS
My Portfolio
Virtual Portfolios
MarketScreener Portfolios
USA Portfolio
European Portfolio
Asian Portfolio
WATCHLISTS
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment Style
Quality stocks
Trend-Following Stocks
Undervalued stocks
Yield stocks
ESG stocks
Momentum stocks
Investment Themes
The SPAC
Luxury
Artificial Intelligence
Europe's family businesses
Water
Sin stocks
RANKINGS
Top News
Most Read News
Hot News
Top Fundamentals
Top Capitalization
Top Yield
Top PER
Top Consensus
Top Fundamentals
Top ranking ESG
Top Technicals
Top RSI
Unusual volumes
Top Gaps
Top STIM
Breakouts
Trends
Top Movers
Top USA
Top Canada
Top U.K.
Top Germany
Top Europe
Top Asia
SCREENERS
Investment Themes
The Cannabis Industry
Strategic Metals
Smart City
Hydrogen
Education
Fintechs
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Growth stocks
Yield stocks
Low valuations
Stock Screener Home
My Screeners
All my stocks
Watchlists
Virtual Portfolios
TOOLS
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Tools
Dynamic Chart
Financial Calendar
Economic Calendar
Sector Research
Currency Converter
ProRealTime Trading
OUR SERVICES
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Our Stock Picks
Thematic Investment Lists
Stock Screener
Homepage
Equities
Japan
Japan Exchange
Takeda Pharmaceutical Company Limited
News
Press Releases
4502
JP3463000004
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(4502)
Add to my list
Report
Delayed Japan Exchange -
02:00 2022-06-27 am EDT
3776.00
JPY
+1.86%
06:02a
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
BU
06/24
Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical
MT
06/22
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
BU
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Summary
Most relevant
All News
Analyst Reco.
Other languages
Press Releases
Official Publications
Sector news
MarketScreener Strategies
Communiqués de presse de la société TAKEDA PHARMACEUTICAL COMPANY LIMITED
06:02a
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficienc..
BU
06/22
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation..
BU
06/10
Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
AQ
06/10
TAKEDA PHARMACEUTICAL
: Notice Concerning Disposal of Treasury Shares under the Long-Term ..
PU
06/09
Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
BU
06/07
Takeda Canada applauds Quebec's new Rare Disease Policy
AQ
06/02
Takeda Pharmaceutical Company Limited - Notice Concerning Withdrawal of Shelf Registrat..
AQ
05/31
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for SpikevaxTM CO..
AQ
05/31
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
BU
05/31
TAKEDA PHARMACEUTICAL
: Current Report by Foreign Issuer (Form 6-K)
PU
05/31
TAKEDA PHARMACEUTICAL
: Current Report by Foreign Issuer (Form 6-K)
PU
05/31
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax&trad..
BU
05/27
TAKEDA PHARMACEUTICAL
: and Seagen to Highlight ADCETRIS Combination Data
PU
05/26
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Signifi..
BU
05/11
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
BU
04/28
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient ..
AQ
04/27
Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories
AQ
04/26
Takeda Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 11
AQ
04/26
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
BU
04/25
TAKEDA PHARMACEUTICAL
: Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 1
PU
04/22
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY&trade..
BU
04/19
Takeda's TAKHZYRO (lanadelumab-flyo) Prefilled Syringe Now Available for People With He..
AQ
04/18
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immuni..
BU
04/18
Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With H..
BU
04/13
Takeda Announces Completion of Acquisition of Own Shares
BU
04/12
Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Childre..
BU
04/09
Exclusive Speaker Interview with Ester Lovsin Barle Ahead of the 6th Annual Highly Pote..
AQ
04/05
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award W..
BU
04/04
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
AQ
04/01
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
BU
03/29
Takeda's TAKHZYRO (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks..
AQ
03/28
Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attack..
BU
03/01
Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment ..
AQ
02/28
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduc..
BU
02/21
Takeda - Alofisel(darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea..
AQ
02/18
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea..
BU
02/16
Ipsen - Cabometyx in combination with Opdivo demonstrated continued survival and qualit..
AQ
02/10
Takeda's Ramona Sequeira Becomes Board Chair of PhRMA
AQ
02/10
Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO (lanad..
AQ
02/04
Takeda Pharmaceutical - Notice of the Revised Forecast of Consolidated Financials for F..
AQ
02/03
Takeda Pharmaceutical Company Limited - Notice of the Revised Forecast of Consolidated ..
AQ
02/03
Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Compet..
AQ
02/03
TAKEDA PHARMACEUTICAL
: Announces Strategic Leadership Changes
PU
02/03
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Refle..
BU
02/03
TAKEDA PHARMACEUTICAL
: Summary of Financial Statements for the Nine-months Period Ended D..
PU
02/03
TAKEDA PHARMACEUTICAL
: Provides Update on Status of Acquisition of Own Shares
PU
02/03
TAKEDA PHARMACEUTICAL
: Notice of the Revised Forecast of Consolidated Financials for FY20..
PU
02/03
TAKEDA PHARMACEUTICAL COMPANY LIMITE
: Notice of the Revised Forecast of Consolidated Fina..
EQ
02/01
FDA Approves Prophylactic Treatment with VONVENDI for Adult Patients Living with Sever..
AQ
01/31
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)..
BU
01/27
TAKEDA PHARMACEUTICAL
: Selects Four New Partners for Annual Global Corporate Social Respo..
PU
01/24
Takeda to Hold Third Quarter FY2021 Earnings Conference Call
AQ
01/21
TAKEDA PHARMACEUTICAL
: to Hold Third Quarter FY2021 Earnings Conference Call
PU
01/19
Takeda Named Global Top Employer for Fifth Consecutive Year
BU
01/12
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40..
AQ
01/11
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta T Cell Engager ..
AQ
01/10
PRESENTATION
: Better health for people, Brighter future for the world
PU
01/10
TAKEDA PHARMACEUTICAL
: Emphasizes Strategy for Delivering Sustainable Growth Over Next De..
PU
01/10
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40..
BU
01/10
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ..
BU
01/05
Takeda to Present at The 40th Annual J.P. Morgan Healthcare Conference
AQ
01/05
TAKEDA PHARMACEUTICAL
: to Present at The 40th Annual JP Morgan Healthcare Conference
PU
2021
TAKEDA PHARMACEUTICAL
: Moderna and the Japanese Government Collaborate to Increase Modern..
PU
2021
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
BU
2021
Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Ch..
AQ
2021
Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Ch..
BU
2021
Takeda Pharmaceutical - Maintaining trust in science is crucial to public health. Here'..
AQ
2021
GENERAL ANNOUNCEMENT
: :Takeda Submits New Drug Application for Novavax COVID-19 Vaccine C..
PU
2021
TAKEDA PHARMACEUTICAL
: Submits New Drug Application for Novavax' COVID-19 Vaccine Candida..
PU
2021
URGENT
: Japan gov't panel OKs Moderna's COVID-19 vaccine as booster
AQ
2021
Takeda Drives Continued Scientific Leadership through Real-World Evidence in Rare Hemat..
AQ
2021
GENERAL ANNOUNCEMENT
: :Share Repurchase Report (From November 1, 2021 to November 30, 202..
PU
2021
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hema..
BU
2021
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENC..
AQ
2021
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENC..
BU
1
2
3
4
5
6
7
8
9
10
Next
Analysis
Takeda, Nintendo among Japanese firms quietly celebrating weak yen
More Must read
Official Publications
2021
Press Release
2021
4th quarter report
2021
Press Release
2021
3rd quarter report
2020
Press Release
2020
Press Release
More Official Publications
Upcoming event on TAKEDA PHARMACEUTICAL COMPANY LIMITED
06/28/22
Annual General Meeting
Company calendar
Upcoming sector events
07/19/22
JOHNSON & JOHNSON
: Interim 2022 Earnings Release
07/21/22
ROCHE HOLDING AG
: Interim 2022 Earnings Release
07/28/22
PFIZER INC.
: Interim 2022 Earnings Release
07/29/22
ABBVIE INC.
: Interim 2022 Earnings Release (Projected)
More events
Sector
Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals
Slave